Log in to save to my catalogue

Claudin 18.2-targeting antibody–drug conjugate CMG901 in patients with advanced gastric or gastro-oe...

Claudin 18.2-targeting antibody–drug conjugate CMG901 in patients with advanced gastric or gastro-oe...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_3153915520

Claudin 18.2-targeting antibody–drug conjugate CMG901 in patients with advanced gastric or gastro-oesophageal junction cancer (KYM901): a multicentre, open-label, single-arm, phase 1 trial

About this item

Full title

Claudin 18.2-targeting antibody–drug conjugate CMG901 in patients with advanced gastric or gastro-oesophageal junction cancer (KYM901): a multicentre, open-label, single-arm, phase 1 trial

Publisher

England: Elsevier Ltd

Journal title

The lancet oncology, 2025-02, Vol.26 (2), p.227-238

Language

English

Formats

Publication information

Publisher

England: Elsevier Ltd

More information

Scope and Contents

Contents

SummaryBackgroundCMG901 is a novel first-in-class antibody–drug conjugate with a humanised anticlaudin 18.2 antibody linked to microtubule-disrupting agent monomethyl auristatin E. We aimed to assess the antitumour activity and safety of CMG901 in patients with advanced gastric or gastro-oesophageal junction cancer and other solid tumours. MethodsK...

Alternative Titles

Full title

Claudin 18.2-targeting antibody–drug conjugate CMG901 in patients with advanced gastric or gastro-oesophageal junction cancer (KYM901): a multicentre, open-label, single-arm, phase 1 trial

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_proquest_miscellaneous_3153915520

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_3153915520

Other Identifiers

ISSN

1470-2045,1474-5488

E-ISSN

1474-5488

DOI

10.1016/S1470-2045(24)00636-3

How to access this item